Relative risks of CKD progression associated with hyperkalemia were similar within the subset of patients receiving renin-angiotensin-aldosterone system inhibitor, across CKD stages, and when alternative definitions of CKD progression were used. This evidence concerns the gene REN and Hyperkalemia.